Compounds as modulators of protein kinases
US-9775841-B2 · Oct 3, 2017 · US
Compounds as modulators of protein kinases
US10220035B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10220035-B2 |
| Application number | US-201514750953-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 25, 2015 |
| Priority date | May 4, 2011 |
| Publication date | Mar 5, 2019 |
| Grant date | Mar 5, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides PI3K protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of kinase mediated diseases or disorders with them.
First claim
Opening claim text (preview).
We claim: 1. A method for the treatment of asthma, comprising the step of administering to a subject in need thereof an effective amount of 2-(1-(4-amino-3-(3-fluoro-4-isopropoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl) ethyl)-5-fluoro-3-(3-fluorophenyl)-4H-chromen-4-one or a pharmaceutically acceptable salt thereof. 2. The method of claim 1 , further comprising the step of administering simultaneously or sequentially to the subject in need thereof at least one other anti-inflammatory agent, immunosuppressive agent, steroid, non-steroidal anti-inflammatory agent, or a mixture thereof. 3. A method for the treatment of asthma, comprising the step of administering to a subject in need thereof an effective amount of (+)-2-(1-(4-amino-3-(3-fluoro-4-isopropoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl) ethyl)-5-fluoro-3-(3-fluorophenyl)-4H-chromen-4-one or a pharmaceutically acceptable salt thereof. 4. The method of claim 3 , further comprising the step of administering simultaneously or sequentially to the subject in need thereof at least one other anti-inflammatory agent, immunosuppressive agent, steroid, non-steroidal anti-inflammatory agent, or a mixture thereof. 5. A method for the treatment of asthma, comprising the step of administering to a subject in need thereof an effective amount of (−)-2-(1-(4-amino-3-(3-fluoro-4-isopropoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl) ethyl)-5-fluoro-3-(3-fluorophenyl)-4H-chromen-4-one or a pharmaceutically acceptable salt thereof. 6. The method of claim 5 , further comprising the step of administering simultaneously or sequentially to the subject in need thereof at least one other anti-inflammatory agent, immunosuppressive agent, steroid, non-steroidal anti-inflammatory agent, or a mixture thereof. 7. A method for the treatment of chronic obstructive pulmonary disease, comprising the step of administering to a subject in need thereof an effective amount of 2-(1-(4-amino-3-(3-fluoro-4-isopropoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl) ethyl)-5-fluoro-3-(3-fluorophenyl)-4H-chromen-4-one or a pharmaceutically acceptable salt thereof. 8. The method of claim 7 , further comprising the step of administering simultaneously or sequentially to the subject in need thereof at least one other anti-inflammatory agent, immunosuppressive agent, steroid, non-steroidal anti-inflammatory agent, or a mixture thereof. 9. A method for the treatment of chronic obstructive pulmonary disease, comprising the step of administering to a subject in need thereof an effective amount of (+)-2-(1-(4-amino-3-(3-fluoro-4-isopropoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl) ethyl)-5-fluoro-3-(3-fluorophenyl)-4H-chromen-4-one or a pharmaceutically acceptable salt thereof. 10. The method of claim 9 , further comprising the step of administering simultaneously or sequentially to the subject in need thereof at least one other anti-inflammatory agent, immunosuppressive agent, steroid, non-steroidal anti-inflammatory agent, or a mixture thereof. 11. A method for the treatment of chronic obstructive pulmonary disease, comprising the step of administering to a subject in need thereof an effective amount of (−)-2-(1-(4-amino-3-(3-fluoro-4-isopropoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl) ethyl)-5-fluoro-3-(3-fluorophenyl)-4H-chromen-4-one or a pharmaceutically acceptable salt thereof. 12. The method of claim 11 , further comprising the step of administering simultaneously or sequentially to the subject in need thereof at least one other anti-inflammatory agent, immunosuppressive agent, steroid, non-steroidal anti-inflammatory agent, or a mixture thereof.
Assignees
Inventors
Classifications
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title
Immunosuppressants, e.g. drugs for graft rejection · CPC title
Immunomodulators · CPC title
Drugs for immunological or allergic disorders · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10220035B2 cover?
- The present invention provides PI3K protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of kinase mediated diseases or disorders with them.
- Who is the assignee on this patent?
- Rhizen Pharmaceuticals Sa
- What technology area does this patent fall under?
- Primary CPC classification A61K31/519. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Mar 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 4 related publications on this page (citations in our corpus or others sharing the same primary CPC).